Bupivacaine Liposomes(BL)

ApprovedSmall molecule

HHuazhong University of Science and Technology

Bupivacaine Liposomes(BL) is one of 2 small molecule programs targeting Bupivacaine. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BupivacaineRecruiting

BupivacaineApproved

Recruiting

Competition

Competitive Landscape

1 competitor in Bupivacaine

#DrugCompanyPhaseTrials

Marcaine

IInnocoll

Approved

31 2

Bupivacaine Liposomes(BL)

HHuazhong University of Science and Technology

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

ApprovedRecruiting

Bupivacaine

NCT06737341

Clinical

Trials by Indication[1]

Interscalene Brachial Plexus Block1 trial

Determination of the Optimal Volume of 0.5% Bupivacaine Liposome in Single-Injection Interscalene Brachial Plexus Block: A Bayesian Phase I/II Trial

Enrolling by invitation·—··NCT06972680·60 enrolled

Bupivacaine1 trial

Effect of Bupivacaine Liposomes or Bupivacaine for Ultrasound-guided CMB on Postoperative Analgesia in Laparoscopic Hepatobiliary Pancreatic Surgery: a Prospective, Single Blind, Completely Randomized, Active Controlled Clinical Trial

Recruiting·HHuazhong University of Science and Technology·Approved·NCT06737341·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Bupivacaine Liposomes(BL). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bupivacaine Liposomes(BL) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bupivacaine Liposomes(BL). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Huazhong University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHuazhong University of Science and Technology

Bupivacaine Liposomes(BL)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Interscalene Brachial Plexus Block1 trial

Bupivacaine1 trial

References

Drug Info

Quick Facts

Related News